| Price | $1.10 |
| Year Range | $0.75 – $1.52 |
| Market Cap | $35M |
| PE Ratio | 3.06 |
| Industry | Biotechnology |
What Is Actinium Pharmaceuticals’s AI Stock Analysis?
Actinium Pharmaceuticals’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Actinium Pharmaceuticals’s momentum in near-real time.
Actinium Pharmaceuticals (ATNM) has an AltIndex AI Score of 43/100, currently a Hold signal. The AI Score distills Actinium Pharmaceuticals's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Actinium Pharmaceuticals’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Actinium Pharmaceuticals — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving ATNM’s AI Score?
Fundamentals
Revenue for the last quarter was $35M. This is an increase of 0.00% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 0.00%, suggesting positive year-over-year growth. Net income for the last quarter was $28M. This is an increase of -605.27% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of -505.66%, suggesting positive year-over-year growth. Ebitda for the last quarter was $28M. This is an increase of -630.78% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of -521.67%, suggesting positive year-over-year growth. The current P/E ratio is 3.06. This may be considered low, potentially indicating undervaluation and a bullish outlook.
See Actinium Pharmaceuticals’s earnings and insider transactions.
Technicals
Today's stock price is $1.10. This represents a decrease of 21.43% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 26.17%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $1.13, which is lower than the previous SMA10 of $1.13. This suggests a potential downward trend in price movement. The RSI is 63.6, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Actinium Pharmaceuticals has an estimated 1 open positions and this number has been stable over the last couple of months indicating a company in a stable position. The business outlook among employees at Actinium Pharmaceuticals is low (an estimate of only 0% of employees have a positive outlook), a concerning sign. Actinium Pharmaceuticals has an estimate of 7,000 visitors to their webpage, with no meaningful increase or decrese in the last couple of months.
Explore Actinium Pharmaceuticals’s job postings, web traffic and app downloads.
Frequently Asked Questions: Actinium Pharmaceuticals AI Stock Analysis
Actinium Pharmaceuticals's AltIndex AI Score is 43/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Actinium Pharmaceuticals a Hold (43/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Actinium Pharmaceuticals — company overview, fundamentals, technicals and alternative data, with a recommendation. See the ATNM AI Score or sign up to read the full thesis.
